Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 2, 2014FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist
Eisai Inc. announced today that FYCOMPA™ (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning...
-
Dec 5, 2013
Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual...
-
Dec 3, 2013Eisai Tackles Stigma Associated With Epilepsy Through Support Of Comic Book Addressing The Condition"Medikidz Explain Epilepsy" Aims to Help Children Better Understand the Disease
Eisai Inc., a leader in the epilepsy community, is proud to announce the availability of a first-of-its-kind comic book in the U.S. designed to...
-
Nov 18, 2013Representatives Will Use Educational Tool for Up to 65,000 Physicians
Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile™ application...
-
Nov 13, 2013BELVIQ® (lorcaserin HCl) CIV Data Featured in Five Abstracts to be Presented at ObesityWeek(SM) 2013
Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from...
-
Nov 13, 2013Eisai to Convene Multidisciplinary Expert Panel in an Effort to Combat Growing Epidemic
A new survey conducted by Eisai Inc., in partnership with the Obesity Action Coalition (OAC) and The Obesity Society (TOS), reveals a...
-
Nov 8, 2013
Eisai Inc. announced today that ACIPHEX® Sprinkle™ Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by...
-
Nov 7, 2013-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications --
SAN DIEGO, CA and WOODCLIFF LAKE, NJ, November 7, 2013 – Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing...
-
Nov 1, 2013Award supports vital research to understand rare and severe form of epilepsy
The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS)...
-
Oct 15, 2013BELVIQ® Sales Force to Double in Size by December 2013
Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200...